First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Ligand Pharmaceuticals Incorporated

    LGND · 4 developments mapped · last assessed 2026-09-24

    Market Ontology has mapped 4 macro, policy, and market developments to Ligand Pharmaceuticals Incorporated since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for LGND yet, so no modelled value is shown. The LGND valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run LGND on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for LGND. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Ligand Pharmaceuticals Incorporated to Acquire AvenCell Therapeutics, Inc. ($47M)

      Ligand is providing financing in exchange for royalties on AvenCell's pipeline assets. This deal structure allows Ligand to gain exposure to potential future drug revenues without the full R&D and operational costs of developing the assets itself. The impact is contingent on AvenCell's clinical succ

      · Moves future royalty stream projections, risk adjusted net present value (rnpv) of pipeline assets, growth rate of royalty revenue

    • Open question

      Ligand Pharmaceuticals Incorporated Follow-On — $6M

      Capital allocation, investment in early-stage biotech, potential future royalty streams, and immediate cash outflow.

      · Moves future revenue growth rate (from royalties), discount rate (risk associated with early stage investment), cash flow projections

    What changed, by assumption

    Future royalty stream projections
    • 2026-09-24Ligand Pharmaceuticals Incorporated to Acquire AvenCell Therapeutics, Inc. ($47M)
    Future revenue growth rate
    • 2026-09-22Ligand Pharmaceuticals Incorporated to Acquire Sydnexis, Inc. ($23M)
    Future revenue growth rate (from royalties)
    • 2026-09-24Ligand Pharmaceuticals Incorporated Follow-On — $6M
    Market share projections for existing hypoparathyroidism treatments
    • 2026-08-27MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-09-24Valuation multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.0.70
    2026-09-24Share countBullishPrimary equity issuance increases diluted share count.0.70
    2026-06-23Share countBullishIssuance of convertible senior notes creates potential future dilution of share count upon conversion.0.90
    2026-06-22Share countBearishRepurchase reduces shares outstanding.0.70
    2026-06-22Interest expenseBullishCoupon adds to interest expense until conversion.0.70
    2026-06-22DilutionBullishConvertible issuance creates contingent dilution at conversion price.0.70
    2026-06-12Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-06-12Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-06-12RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-24Ligand Pharmaceuticals Incorporated Follow-On — $6Mmixed1-3m0.40
    2026-09-24Ligand Pharmaceuticals Incorporated to Acquire AvenCell Therapeutics, Inc. ($47M)Bullish1-5y0.60
    2026-09-22Ligand Pharmaceuticals Incorporated to Acquire Sydnexis, Inc. ($23M)Bullish1-5y0.60
    2026-08-27MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trialwatch1-5y0.10